1. Home
  2. DAWN vs TOVX Comparison

DAWN vs TOVX Comparison

Compare DAWN & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • TOVX
  • Stock Information
  • Founded
  • DAWN 2018
  • TOVX 2001
  • Country
  • DAWN United States
  • TOVX United States
  • Employees
  • DAWN N/A
  • TOVX N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • TOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • DAWN Health Care
  • TOVX Health Care
  • Exchange
  • DAWN Nasdaq
  • TOVX Nasdaq
  • Market Cap
  • DAWN N/A
  • TOVX 3.8M
  • IPO Year
  • DAWN 2021
  • TOVX 2006
  • Fundamental
  • Price
  • DAWN $6.80
  • TOVX $0.44
  • Analyst Decision
  • DAWN Strong Buy
  • TOVX Hold
  • Analyst Count
  • DAWN 7
  • TOVX 1
  • Target Price
  • DAWN $31.57
  • TOVX N/A
  • AVG Volume (30 Days)
  • DAWN 1.3M
  • TOVX 238.4K
  • Earning Date
  • DAWN 07-29-2025
  • TOVX 08-12-2025
  • Dividend Yield
  • DAWN N/A
  • TOVX N/A
  • EPS Growth
  • DAWN N/A
  • TOVX N/A
  • EPS
  • DAWN N/A
  • TOVX N/A
  • Revenue
  • DAWN $161,922,000.00
  • TOVX N/A
  • Revenue This Year
  • DAWN $17.98
  • TOVX N/A
  • Revenue Next Year
  • DAWN $49.50
  • TOVX N/A
  • P/E Ratio
  • DAWN N/A
  • TOVX N/A
  • Revenue Growth
  • DAWN N/A
  • TOVX N/A
  • 52 Week Low
  • DAWN $6.08
  • TOVX $0.40
  • 52 Week High
  • DAWN $16.76
  • TOVX $7.37
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 55.46
  • TOVX 36.05
  • Support Level
  • DAWN $6.22
  • TOVX $0.42
  • Resistance Level
  • DAWN $6.95
  • TOVX $0.46
  • Average True Range (ATR)
  • DAWN 0.25
  • TOVX 0.03
  • MACD
  • DAWN 0.04
  • TOVX 0.02
  • Stochastic Oscillator
  • DAWN 80.11
  • TOVX 25.00

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: